OBJECTIVE: We assessed the effect of folic acid (FA) on the pharmacokinetics and pharmacodynamics of low-dose oral methotrexate (MTX) during the remission-induction phase of psoriasis treatment. METHODS: In a 32-week, open-label, two-way cross-over study, patients (n=20, seven men, aged 35-70 years) with moderate-to-severe plaque psoriasis were randomly assigned to receive MTX plus FA (20 mg/week) for 16 weeks followed by MTX monotherapy (three doses of MTX separated by 12-h intervals once a week) for an additional 16 weeks (treatment arm A, n=10) or to receive the opposite sequence of treatments (arm B, n=10). Dosing of MTX was individualised with the help of pre-study evaluation of plasma MTX pharmacokinetics. The Psoriasis Area and Severity Index (PASI), biochemistry and haematology tests and erythrocyte concentration of MTX polyglutamates (MTXPG) were evaluated throughout the study. RESULTS: In arms A and B, the mean (range) concentrations of MTXPG (nmol/L) were comparable [week 16: 96.2 (32.0-157) vs. 111 (73.7-175), P=0.32; week 32: 103 (55.8-173) vs. 83.6 (27.4-129), P=0.24]. After 16 weeks, the mean+/-SEM PASI decreased from 20.1+/-2.1 to 8.8+/-1.3 in arm A, while a greater reduction from 27.2+/-2.1 to 5.1+/-1.0 occurred in arm B (P<0.001). Positive correlations were found between the percent improvement in PASI at week 16 and the ratios of the concentration of MTXPG to plasma folate (rho=0.59, P=0.008) or RBC folate concentration (rho=0.56, P=0.013). Due to an accelerated decline in PASI in arm A and a trend to its worsening in arm B after crossing over of treatments, the mean absolute PASI scores in both arms were comparable at week 32. CONCLUSION: The antipsoriatic effect of MTX during the remission-induction phase of treatment is influenced by folate status and may be significantly less if combined treatment with FA is used, irrespective of pre-treatment folate levels. The individual tailoring of MTX dosing needs further attention because the mean percent PASI improvement from baseline was 83% and the inter-patient variability in response was low after 16 weeks of monotherapy with MTX.

Department of Pharmacology Faculty of Medicine Charles University Simkova 870 500 38 Hradec Kralove Czech Republic

Zobrazit více v PubMed

Ann Intern Med. 1994 Dec 1;121(11):833-41 PubMed

Eur J Clin Pharmacol. 1998 Feb;53(6):437-44 PubMed

Cancer Chemother Pharmacol. 1988;21(2):145-9 PubMed

Br J Clin Pharmacol. 2002 Aug;54(2):147-56 PubMed

J Eur Acad Dermatol Venereol. 2000 Sep;14(5):382-8 PubMed

Clin Chem. 2003 Oct;49(10):1632-41 PubMed

J Eur Acad Dermatol Venereol. 2005 Mar;19(2):196-202 PubMed

Br J Dermatol. 2006 Jun;154(6):1169-74 PubMed

Rheumatology (Oxford). 2004 Mar;43(3):267-71 PubMed

Clin Pharmacokinet. 2003;42(2):139-51 PubMed

J Rheumatol. 1995 Jan;22(1):38-40 PubMed

J Rheumatol. 2000 Sep;27(9):2110-4 PubMed

J Am Acad Dermatol. 2005 Oct;53(4):652-9 PubMed

J Rheumatol. 2006 Jul;33(7):1442-6 PubMed

J Am Acad Dermatol. 2004 Feb;50(2):301-9 PubMed

J Rheumatol. 1998 Mar;25(3):441-6 PubMed

Cancer. 1981 Dec 1;48(11):2427-32 PubMed

J Nutr. 2003 May;133(5):1272-80 PubMed

Rheumatology (Oxford). 2002 Jun;41(6):658-65 PubMed

Ann Rheum Dis. 1994 Jul;53(7):475-7 PubMed

Br J Dermatol. 2005 Apr;152(4):597-615 PubMed

Arthritis Rheum. 2001 Jul;44(7):1515-24 PubMed

J Rheumatol. 2004 Dec;31(12):2374-81 PubMed

Basic Clin Pharmacol Toxicol. 2005 Mar;96(3):247-8 PubMed

N Engl J Med. 2003 Aug 14;349(7):658-65 PubMed

Aliment Pharmacol Ther. 2003 Jul 1;18(1):57-63 PubMed

Arthritis Rheum. 2006 May;54(5):1366-77 PubMed

Assessment of Erythrocytes Methotrexate Polyglutamate Three Levels in Psoriatic Patients Treated with Methotrexate Monotherapy and Their Association with Disease Response